{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:58:06Z","timestamp":1790888286382,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ymthe.2022.02.022","type":"journal-article","created":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T11:31:46Z","timestamp":1645615906000},"page":"1801-1809","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Global challenges in preparedness and response to epidemic infectious diseases"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1426-3680","authenticated-orcid":false,"given":"Piero","family":"Olliaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els","family":"Torreele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2022.02.022_bib1","series-title":"Principles of Epidemiology in Public Health Practice","year":"2006"},{"key":"10.1016\/j.ymthe.2022.02.022_bib2","doi-asserted-by":"crossref","first-page":"17034","DOI":"10.1038\/nrdp.2017.34","article-title":"Obesity","volume":"3","author":"Gonz\u00e1lez-Muniesa","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymthe.2022.02.022_bib3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1146\/annurev-pharmtox-010617-052534","article-title":"The opioid epidemic: crisis and solutions","volume":"58","author":"Skolnick","year":"2018","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ymthe.2022.02.022_bib4","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1016\/S0140-6736(15)60858-3","article-title":"Global health security: the wider lessons from the west African Ebola virus disease epidemic","volume":"385","author":"Heymann","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.02.022_bib5","series-title":"17 Sustainable Development Goals","year":"2015"},{"key":"10.1016\/j.ymthe.2022.02.022_bib6","article-title":"Surgisphere: Governments and WHO changed Covid-19 policy based on suspect data from tiny US Company (2020)","author":"Davey","year":"2020","journal-title":"The Guardian"},{"key":"10.1016\/j.ymthe.2022.02.022_bib7","series-title":"Goldman Sachs Asks in Biotech Research Report: \u2018Is Curing Patients a Sustainable Business Model?\u2019 CNBC 18 April","author":"Kim","year":"2018"},{"key":"10.1016\/j.ymthe.2022.02.022_bib8","article-title":"Vaccine inequity undermining global economic recovery","volume":"22","year":"2021","journal-title":"News Release"},{"key":"10.1016\/j.ymthe.2022.02.022_bib9","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0140-6736(21)00503-1","article-title":"Urgent lessons from COVID 19: why the world needs a standing, coordinated system and sustainable financing for global research and development","volume":"27","author":"Lurie","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.02.022_bib10","article-title":"Preparing for the next pandemic requires public health-focused industrial policy","author":"Torreele","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ymthe.2022.02.022_bib12","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12874-021-01324-8","article-title":"Delays in reporting and publishing trial results during pandemics: cross sectional analysis of 2009 H1N1, 2014 Ebola, and 2016 Zika clinical trials","volume":"21","author":"Jones","year":"2021","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.ymthe.2022.02.022_bib13","author":"Lowe"},{"key":"10.1016\/j.ymthe.2022.02.022_bib14","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1186\/s13063-021-05323-4","article-title":"Chemoprophylaxis trial designs in epidemics: insights from a systematic review of COVID-19 study registrations","volume":"22","author":"Manoharan","year":"2021","journal-title":"Trials"},{"key":"10.1016\/j.ymthe.2022.02.022_bib15","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1016\/S1473-3099(17)30234-7","article-title":"Insights from clinical research completed during the west Africa Ebola virus disease epidemic","volume":"17","author":"Rojek","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.02.022_bib16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S1473-3099(17)30698-9","article-title":"Initiation and publication time-lags of treatment trials for Ebola virus disease","volume":"18","author":"Olliaro","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.02.022_bib18","unstructured":"Centers for Disease Control and Prevention. Asian Lineage Avian Influenza A\/H7N)) Virus. https:\/\/www.cdc.gov\/flu\/avianflu\/h7n9-virus.htm"},{"key":"10.1016\/j.ymthe.2022.02.022_bib19","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1093\/ofid\/ofz359.028","article-title":"The PALM Consortium: a multicenter, multi-outbreak randomized controlled trial of Ebola virus disease therapeutics","volume":"6","author":"Mulangu","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.02.022_bib21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12916-020-01732-5","article-title":"Compassionate drug (mis)use during pandemics: lessons for COVID-19 from 2009","volume":"18","author":"Rojek","year":"2020","journal-title":"BMC Med."},{"key":"10.1016\/j.ymthe.2022.02.022_bib22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S1473-3099(13)70327-X","article-title":"Open source clinical science for emerging infections","volume":"14","author":"Dunning","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.02.022_bib23","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S1473-3099(20)30440-0","article-title":"Global outbreak research: harmony not hegemony","volume":"20","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.02.022_bib24","unstructured":"International Severe Acute Respiratory and emerging Infection Consortium. ISARIC Covid-19 Timeline 2019-2021. https:\/\/isaric.org\/covid-19-pandemic-response-timeline\/."},{"key":"10.1016\/j.ymthe.2022.02.022_bib25","article-title":"ISARIC COVID-19 clinical data report Issued: 15 December 2021","author":"Baillie","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.ymthe.2022.02.022_bib26","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S1473-3099(21)00565-X","article-title":"The value of open-source clinical science in pandemic response: lessons from ISARIC","volume":"21","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.02.022_bib27","author":"Irwin"},{"key":"10.1016\/j.ymthe.2022.02.022_bib29","doi-asserted-by":"crossref","first-page":"e000709","DOI":"10.1136\/bmjgh-2018-000709","article-title":"Why miltefosine, a life-saving drug for leishmaniasis, is unavailable to people who need it the most","volume":"3","author":"Sunyoto","year":"2018","journal-title":"BMJ Glob. Health"},{"key":"10.1016\/j.ymthe.2022.02.022_bib30","author":"Torreele"},{"key":"10.1016\/j.ymthe.2022.02.022_bib31","article-title":"Ebola vaccine to be made available to countries for outbreak response","volume":"12","year":"2021","journal-title":"News Release"},{"key":"10.1016\/j.ymthe.2022.02.022_bib34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1473-3099(21)00125-0","article-title":"Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial","volume":"22","author":"Ishola","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ymthe.2022.02.022_bib35","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/s41591-021-01393-8","article-title":"After COVID-19 successes, researchers push to develop mRNA vaccines for other diseases","volume":"27","author":"May","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2022.02.022_bib36","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41541-021-00356-x","article-title":"Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic","volume":"6","author":"Mendon\u00e7a","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.ymthe.2022.02.022_bib38","author":"Hoecklin"},{"key":"10.1016\/j.ymthe.2022.02.022_bib39","unstructured":"The New York Times Corona Virus Tracker. https:\/\/www.nytimes.com\/interactive\/2020\/science\/coronavirus-vaccine-tracker.html."},{"key":"10.1016\/j.ymthe.2022.02.022_bib40","series-title":"G20\u2019s Bitter Divide on Global Vaccine Inequality Could Condemn World to an \u201cEndless Pandemic\u201d, Charities Warn","year":"2021"},{"key":"10.1016\/j.ymthe.2022.02.022_bib41","unstructured":"United Nations Development Program. Global Dashboard for Vaccine Equity, https:\/\/data.undp.org\/vaccine-equity\/."},{"key":"10.1016\/j.ymthe.2022.02.022_bib42","unstructured":"Our World in Data Coronavirus (COVID-19) Vaccinations, https:\/\/ourworldindata.org\/covid-vaccinations."},{"key":"10.1016\/j.ymthe.2022.02.022_bib43","series-title":"WHO chief warns against \u2018catastrophic moral failure\u2019 in COVID-19 vaccine access","year":"2021"},{"key":"10.1016\/j.ymthe.2022.02.022_bib44","series-title":"Designing vaccines for people, not profits","author":"Mazzucato","year":"2020"},{"key":"10.1016\/j.ymthe.2022.02.022_bib45","series-title":"The Omicron Variant Reveals the True Global Danger of \u2018vaccine Apartheid\u2019","author":"Elliott","year":"2021"},{"key":"10.1016\/j.ymthe.2022.02.022_bib46","series-title":"Solidarity Call to Action. Making the Response to COVID-19 a Public Common Good","year":"2020"},{"key":"10.1016\/j.ymthe.2022.02.022_bib47","series-title":"Countries Obstructing COVID-19 Patent Waiver Must Allow Negotiations to Start","year":"2021"},{"key":"10.1016\/j.ymthe.2022.02.022_bib48","author":"Torreele"},{"key":"10.1016\/j.ymthe.2022.02.022_bib49","doi-asserted-by":"crossref","first-page":"m3209","DOI":"10.1136\/bmj.m3209","article-title":"The rush to create a COVID-19 vaccine can do more harm than good","volume":"370","author":"Torreele","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.ymthe.2022.02.022_bib50","doi-asserted-by":"crossref","first-page":"e067488","DOI":"10.1136\/bmj-2021-067488","article-title":"Vaccines, therapeutics, and diagnostics for covid-19: redesigning systems to improve pandemic response","volume":"375","author":"Ramchandani","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ymthe.2022.02.022_bib51","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/d41586-022-00324-y","article-title":"Re-orient biomedical R&D towards the global public interest","volume":"602","author":"Swaminathan","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2022.02.022_bib52","series-title":"Governing Health Innovation for the Common Good","year":"2021"},{"key":"10.1016\/j.ymthe.2022.02.022_bib53","series-title":"Moderna\u2019s Claim of Favorable Results in its Vaccine Trial Is an Example of \u2018publication by Press Release\u2019","author":"Haseltine","year":"2020"},{"key":"10.1016\/j.ymthe.2022.02.022_bib54","article-title":"Transparency of COVID-19 vaccine trials: decisions without data","author":"Tanveer","year":"2021","journal-title":"BMJ Evid. Based Med."},{"key":"10.1016\/j.ymthe.2022.02.022_bib55","article-title":"What the Tamiflu Saga tells us about drug trials and big pharma","author":"Goldacre","year":"2014","journal-title":"The Guardian"},{"key":"10.1016\/j.ymthe.2022.02.022_bib56","article-title":"Clinical trial disclosure and data transparency: obligation or opportunity?","author":"Zaninelli","year":"2021","journal-title":"Applied Clinical Trials"},{"key":"10.1016\/j.ymthe.2022.02.022_bib57","doi-asserted-by":"crossref","first-page":"e1003894","DOI":"10.1371\/journal.pmed.1003894","article-title":"Reporting bias in clinical trials: progress toward transparency and next steps","volume":"19","author":"Mitra-Majumdar","year":"2022","journal-title":"PLoS Med."},{"key":"10.1016\/j.ymthe.2022.02.022_bib58","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/s41467-021-21134-2","article-title":"Potential health and economic impacts of dexamethasone treatment for patients with COVID-19","volume":"12","author":"\u00c1guas","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2022.02.022_bib59","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with covid-19","volume":"384","author":"Horby","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.02.022_bib60","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.02.022_bib61","article-title":"Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.ymthe.2022.02.022_bib62","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1056\/NEJMoa2022926","article-title":"Effect of hydroxychloroquine in hospitalized patients with covid-19","volume":"383","author":"Horby","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2022.02.022_bib63","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(20)32013-4","article-title":"Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"396","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.02.022_bib64","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(21)00897-7","article-title":"Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.02.022_bib65","article-title":"Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.ymthe.2022.02.022_bib66","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0140-6736(21)00149-5","article-title":"Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2022.02.022_bib67","article-title":"Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.ymthe.2022.02.022_bib69","author":"Krauskopf"},{"key":"10.1016\/j.ymthe.2022.02.022_bib70","article-title":"Increase transparency at the FDA: we need sunlight to fight the pandemic","volume":"29","author":"Bendicksen","year":"2020","journal-title":"STAT. First Opin."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162200106X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152500162200106X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:02:32Z","timestamp":1761501752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152500162200106X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S152500162200106X"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2022.02.022","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Global challenges in preparedness and response to epidemic infectious diseases","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2022.02.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s).","name":"copyright","label":"Copyright"}]}}